Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Grieving elephant to receive experimental cannabidiol treatment
The elephants will receive the CBD oil either directly through their mouths or it will be mixed into their food.
Project will monitor eliphant's stress levels before and after taking CBD oil.

A female African elephant has become the first animal at Warsaw Zoo, Poland, to receive an experimental treatment involving cannabidiol to see if it will relieve symptoms of anxiety and depression.

Young Fredzia has been showing signs of stress since the death of her herd-mate, Erna, earlier this year. Noticing that Fredzia was struggling to adapt and form bonds with the other herd-members, keepers launched a project to see if cannabis-extract oil would relieve her symptoms and restore some balance to the herd.

Dr Agnieszka Czujkowska, head of the zoo's Animal Rehabilitation Department, told BBC News: "This is a huge game-changer in every elephant group. Elephants might have behavioural problems when the structure of a group changes.”

Cannabidiol, or CBD oil, originates from a cannabis plant compound and is thought to stimulate the production of serotonin and dopamine, two chemicals known to affect overall mood. Although it derives from cannabis, CBD oil does not have any intoxicating properties.

The first stage of the experiment has already been completed, with keepers collecting faeces, saliva and blood samples from Fredzia and her herd-mates to monitor their cortisol levels. The team plan to measure the cortisol levels again, once the CBD oil has been administered either directly through the elephant's mouths or mixed in with their food.

Dr Czujkowska said: “We are planning to give them the CBD and measure the cortisol again. This is the experiment. Then we know for sure [the oil] is working or not.”

She added: "It's not very potent. The only side effect will be some behavioural changes. We will have to manage these to achieve the results we want."

Products containing CBD oil for humans and pets are widely available in many countries, but some safety concerns have been raised. In 2019, two cannabidiol-based products used to treat MS and epilepsy received NHS approval for use in England.

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.